专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5928650A Subunit vaccine against Neisseria meningitidis infections and corresponding subunits in the purified state 失效
标题翻译：亚单位疫苗针对脑膜炎奈瑟菌感染和相应的亚单位处于纯化状态
公开(公告)号：US5928650A
公开(公告)日：1999-07-27
申请号：US449733
申请日：1995-05-25
申请人： Marie Jose Quentin-Millet , Ling Lissolo
发明人： Marie Jose Quentin-Millet , Ling Lissolo
IPC分类号： A61K39/095 , A61K38/00 , A61K39/00 , A61P31/04 , C07K1/00 , C07K1/22 , C07K14/195 , C07K14/22 , C07K14/41 , C07K14/81 , C12P21/02 , C12R1/36
CPC分类号： C07K14/22 , A61K38/00 , A61K39/00 , Y10S435/871
摘要： The present invention relates to the lower molecular weight subunit of the human transferrin receptor of a strain of N. meningitidis, in purified form, as well as to a vaccinal pharmaceutical composition intended for the prevention or attenuation of the effects of an N. meningitidis infection, containing the said subunit in purified form.
摘要翻译：本发明涉及纯化形式的脑膜炎奈瑟氏球菌菌株的人转铁蛋白受体的较低分子量亚基，以及旨在预防或减弱脑膜炎奈瑟菌感染影响的疫苗药物组合物，含有纯化形式的所述亚基。

2. 发明授权

US5045203A Separation of protein antigens of Bordetella bacteria by affinity chromatography 失效
标题翻译：通过亲和层析分离Bordetella细菌的蛋白质抗原
公开(公告)号：US5045203A
公开(公告)日：1991-09-03
申请号：US629674
申请日：1990-12-18
申请人： Marie-Jose Quentin-Millet , Francois Arminjon
发明人： Marie-Jose Quentin-Millet , Francois Arminjon
IPC分类号： C07K14/195 , A61K39/00 , A61K39/10 , B01J20/281 , C07K1/16 , C07K1/22 , C07K14/235 , C07K14/41 , C07K17/02 , C07K17/14 , C12N11/00 , C12P21/00 , C12R1/01 , G01N30/88 , G01N33/50 , G01N33/569
CPC分类号： C07K14/235 , A61K39/00 , Y10S530/825
摘要： A chromatography material comprises a solid support on which is fixed, as a ligan, desialyled gycolprotein selected from desialyled fetuin and desialyled haptoglobin. This material is used to purify protein antigens of bacteria of the Bordetella genus.

3. 发明申请

US20110206730A1 Dengue Chimeric Viruses 有权
标题翻译：登革热嵌合病毒
公开(公告)号：US20110206730A1
公开(公告)日：2011-08-25
申请号：US13102685
申请日：2011-05-06
申请人： Marie-Jose Quentin-Millet
发明人： Marie-Jose Quentin-Millet
IPC分类号： A61K39/12 , C12N7/01 , C12N15/40 , C07K14/18 , A61P37/04
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , C07K14/005 , C12N9/127 , C12N2770/24121 , C12N2770/24122 , C12N2770/24134 , Y02A50/386 , Y02A50/388
摘要： The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.
摘要翻译：本发明涉及不容易累积点突变和遗传变异的登革热嵌合病毒。在这些登革热嵌合病毒中，编码聚合酶的NS5基因已被黄热病病毒的相应NS5序列替代。

4. 发明申请

US20100215692A1 Dengue Chimeric Viruses 有权
标题翻译：登革热嵌合病毒
公开(公告)号：US20100215692A1
公开(公告)日：2010-08-26
申请号：US11619687
申请日：2007-01-04
申请人： Marie-Jose QUENTIN-MILLET
发明人： Marie-Jose QUENTIN-MILLET
IPC分类号： A61K39/295 , C12N7/01 , C07H21/04 , C07K14/08 , A61K39/12 , A61P31/14
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , C07K14/005 , C12N9/127 , C12N2770/24121 , C12N2770/24122 , C12N2770/24134 , Y02A50/386 , Y02A50/388
摘要： The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.
摘要翻译：本发明涉及不容易累积点突变和遗传变异的登革热嵌合病毒。在这些登革热嵌合病毒中，编码聚合酶的NS5基因已被黄热病病毒的相应NS5序列替代。

5. 发明申请

US20080107685A1 Live Attenuated Dengue 3 Virus Strains 审中-公开
标题翻译：活的减毒登革热3病毒株
公开(公告)号：US20080107685A1
公开(公告)日：2008-05-08
申请号：US11756790
申请日：2007-06-01
申请人： Veronique Barban , Marie-Jose Quentin-Millet , Regis Sodoyer
发明人： Veronique Barban , Marie-Jose Quentin-Millet , Regis Sodoyer
IPC分类号： A61K39/00 , C07H21/00 , C07K14/00 , C12N7/04
CPC分类号： C07K14/005 , A61K2039/5254 , C12N7/00 , C12N2770/24122 , C12N2770/24161 , Y02A50/386
摘要： The invention relates to live attenuated dengue serotype 3 virus strains which have been produced by site directed mutagenesis of an attenuated dengue 3 strain.
摘要翻译：本发明涉及通过减毒登革热3菌株的定点诱变产生的减毒登革热血清型3病毒株。

6. 发明授权

US5618541A Vaccine against Neisseria meningitidis infections 失效
标题翻译：疫苗针对脑膜炎奈瑟菌感染
公开(公告)号：US5618541A
公开(公告)日：1997-04-08
申请号：US66167
申请日：1993-06-02
申请人： Marie-Jose Quentin-Millet
发明人： Marie-Jose Quentin-Millet
IPC分类号： A61K39/095 , A61K38/00 , A61P31/04 , C07K1/22 , C07K14/195 , C07K14/22 , C07K14/41 , C07K14/705 , C12P21/02 , C12R1/36 , A61K31/075
CPC分类号： C07K14/22 , A61K38/00 , Y10S435/871
摘要： A vaccinal pharmaceutical composition which comprises, as therapeutic agents, at least a first and a second molecule capable of binding to human transferrin; the said first molecule originating from a first strain of N. meningitidis which possesses a human transferrin receptor in which the lower molecular weight subunit (Tbp2) is recognised by an antiserum to the receptor of N. meningitidis strain 2394 (receptor 2394) and is not recognised by an antiserum to the receptor of N. meningitidis strain 2169 (receptor 2169); and at least a second molecule originating from a second strain of N. meningitidis which possesses a human transferrin receptor in which the lower molecular weight subunit (Tbp2) is recognised by an anti-receptor 2169 antiserum and is not recognised by an anti-receptor 2394 antiserum.
摘要翻译： PCT No.PCT / FR92 / 00905 Sec。 371日期：1993年6月2日 102（e）日期1993年6月2日PCT提交1992年9月29日PCT公布。出版物WO93 / 06861 日期：1993年04月15日一种疫苗药物组合物，其包含至少一种能够结合人转铁蛋白的第一和第二分子作为治疗剂; 所述第一分子源自具有人类转铁蛋白受体的脑膜炎奈瑟氏球菌的第一菌株，其中低分子量亚基（Tbp2）被脑膜炎奈瑟氏球菌菌株2394（受体2394）的受体的抗血清识别，并且不是被脑膜炎奈瑟氏球菌菌株2169（受体2169）的受体的抗血清识别; 和至少一种源自第二脑膜炎奈瑟氏球菌菌株的第二分子，其具有人类转铁蛋白受体，其中低分子量亚基（Tbp2）被抗受体2169抗血清识别，并且不被抗受体2394识别抗血清

7. 发明授权

US07968102B2 Dengue chimeric viruses 有权
标题翻译：登革热嵌合病毒
公开(公告)号：US07968102B2
公开(公告)日：2011-06-28
申请号：US11619687
申请日：2007-01-04
申请人： Marie-Jose Quentin-Millet
发明人： Marie-Jose Quentin-Millet
IPC分类号： A61K39/12 , A61K39/295
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , C07K14/005 , C12N9/127 , C12N2770/24121 , C12N2770/24122 , C12N2770/24134 , Y02A50/386 , Y02A50/388
摘要： The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.
摘要翻译：本发明涉及不容易累积点突变和遗传变异的登革热嵌合病毒。在这些登革热嵌合病毒中，编码聚合酶的NS5基因已被黄热病病毒的相应NS5序列替代。

8. 发明授权

US08227587B2 Dengue chimeric viruses 有权
标题翻译：登革热嵌合病毒
公开(公告)号：US08227587B2
公开(公告)日：2012-07-24
申请号：US13102685
申请日：2011-05-06
申请人： Marie-Jose Quentin-Millet
发明人： Marie-Jose Quentin-Millet
IPC分类号： C07H21/00 , A61K39/12
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , C07K14/005 , C12N9/127 , C12N2770/24121 , C12N2770/24122 , C12N2770/24134 , Y02A50/386 , Y02A50/388
摘要： The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.
摘要翻译：本发明涉及不容易累积点突变和遗传变异的登革热嵌合病毒。在这些登革热嵌合病毒中，编码聚合酶的NS5基因已被黄热病病毒的相应NS5序列替代。

9. 发明授权

US6126938A Methods for inducing a mucosal immune response 失效
标题翻译：诱导粘膜免疫应答的方法
公开(公告)号：US6126938A
公开(公告)日：2000-10-03
申请号：US18460
申请日：1998-02-04
申请人： Bruno Guy , Jean Haensler , Marie-Jose Quentin-Millet
发明人： Bruno Guy , Jean Haensler , Marie-Jose Quentin-Millet
IPC分类号： A61K38/00 , A61K39/00 , A61K39/106 , A61P31/04 , C12N9/80 , C12N15/57
CPC分类号： A61K39/105 , C12N9/80 , A61K2039/51 , A61K2039/541 , A61K2039/55511 , A61K2039/55555 , A61K38/00 , Y10S424/812
摘要： The invention relates to a pharmaceutical composition intended for inducing in a host mammal a protective immune response against an antigen, at a mucosal effector site, which comprises at least two identical or different products each containing an inducing agent for the immune response, selected from the antigen and, provided the antigen is protein in nature, an expression cassette capable of expressing the antigen, for a concomitant or consecutive administration; one of the products being formulated so as to be administered via the nasobuccal route so that the inducing agent is targeted to the inducer site(s) for an immune response in the naso-oropharynx or the salivary glands, the other product being formulated so as to be administered via a suitable mucosal route other than the nasal route, so that the inducing agent is targeted to the inducer site(s) for an immune response at the effector site at which the immune response is sought. Optionally, such a composition can also comprise a third product, identical to or different from the first two, formulated for systemic administration.
摘要翻译：本发明涉及用于在宿主哺乳动物中诱导针对抗原的保护性免疫应答的药物组合物，其在粘膜效应部位包含至少两种相同或不同的产物，其各自含有用于免疫应答的诱导剂，其选自抗原，并且如果抗原是蛋白质，则能够表达抗原的表达盒用于伴随或连续施用; 其中一种产品被配制成通过鼻塞途径施用，使得诱导剂靶向于在鼻咽或唾液腺中的免疫应答的诱导物位点，其他产物被配制成通过除了鼻道以外的合适的粘膜途径施用，使得诱导剂靶向诱导物位点，用于在寻求免疫应答的效应部位处的免疫应答。任选地，这样的组合物还可以包含配制用于全身给药的与前两个相同或不同的第三产物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式